Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases
Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Summary
The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed/refractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an informed consent form and undergoing single nucleus cell collection and pretreatment, and blood was collected before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations.
Official title: CD7CAR-T Cell Therapy As a Single-Arm, Open-Label, Single-Center Investigator-Initiated Early-Stage Clinical Study
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2025-03-18
Completion Date
2027-03-31
Last Updated
2025-03-12
Healthy Volunteers
No
Interventions
T cell injection targeting CD7 chimeric antigen receptor
Subjects who sign the informed consent form and meet the inclusion/exclusion criteria will be entered into the 0.25×108, 1×108 and 2×108 CAR-T groups, in order of priority, and will be administered 1 dose of
Locations (1)
PersonGen.Anke Cellular Therapeutice Co. Ltd
Hefei, Anhui, China